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Abstract
Background: Subcutaneous peripheral nerve stimulation (PNS) has emerged as a useful tool in the treatment of intractable
headaches. However, complications such as skin erosion, infection and lead migration have adversely affected clinical outcome,
and occasionally led to treatment cessation.
Objectives: Here we report the results of peripheral nerve stimulator implantation performed on 24 patients with various chronic
headaches at our center over a period of 9 years. We describe the complications of the procedure and their prevention with a mod-
ified surgical technique.
Patients andMethods: We searched our database for patients with chronic refractory headaches who had undergone PNS. Patients
were assessed before being considered for PNS, and their pain characteristics were reviewed. Following a successful trial, patients
were implanted with a permanent peripheral nerve stimulator. Selection of target nerves was based on headache diagnosis and
head pain characteristics. Patients were followed for an average of 4.9 years. Headache characteristics before and after treatment
were compared.
Results: Twenty four patients were included in the study. All patients reported on improvement in head pain intensity, duration
and frequency three months after permanent device implantation Mean total pain index (TPI) decreased significantly, from 516± 131
before the procedure to 74.8± 61.6 at the last follow up (P < 0.00001). There were no acute post-operative infections. Three patients
had their stimulator removed. The self-rated treatment satisfaction was excellent in 54% of the patients, very good or good in 42%,
and fair in 4%.
Conclusions: Our results support the use of PNS in some patients with refractory chronic headaches. Appropriate surgical planning
and technique are important to achieve good clinical outcome and to minimize complications.
Keywords: Headache, Cranial Nerves, Peripheral Nerve Stimulation, Occipital Nerve, Supraorbital Nerve, Auriculotemporal Nerve,
Complication
1. Background
Peripheral nerve stimulation (PNS) refers to the place-
ment of a lead near the anatomic location of a nerve to
directly stimulate it (1). This technique has been used
to the cranial nerves for treatment of chronic intractable
headache of various types (2-4), including migraine (5-
7), cluster headache (8, 9), occipital neuralgia (10, 11) cer-
vicogenic headache (12) and supraorbital neuralgia (13).
Promising outcomes have been reported, with efficacy
rates in pain reduction and functional improvement rang-
ing from 40% to100% (2-4, 8, 14, 15). While this positive
response is encouraging, complications of the therapy,
that include acute and late-onset infections, lead migra-
tion and skin erosion, have been of concern (3, 4, 6-8, 14-
16). These complications significantly impact the clinical
application of this treatment modality, and could impede
a more widespread use of it in the future.
2. Objectives
Here we report the results of peripheral nerve stimu-
lator implantation performed on 24 patients with various
chronic headaches at our center over a period of 9 years.
We describe the complications of the procedure and their
prevention with a modified surgical technique.
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3. Patients andMethods
This was a retrospective chart review, conducted at a
large academic medical center in an urban setting and at a
private practice pain center. The study was approved by the
Thomas Jefferson University institutional review board. All
patients were initially evaluated for headaches. The study
period was from August 2006 to January 2015.
We searched our database for patients] with chronic
refractory headaches, who had undergone PNS for this
indication. These patients had failed multiple conserva-
tive therapies, including medications, psychotherapy and
physical therapy. They were referred by headache special-
ists to consider PNS therapy.
All patients were thoroughly evaluated at our center by
one of the authors (LZ). They also underwent a psycholog-
ical evaluation before a PNS trial was considered. The deci-
sion as to which scalp nerve to target for stimulation was
based on the patient’s clinical presentation and headache
diagnosis. For patients who experienced > 50% headache
reduction during the 7 day trial, implantation of a perma-
nent PNS was approved (of the total patients who under-
went the trial, all but one met the above criterion, received
a permanent PNS implantation, and participated in the
study). Implantation areas included the occipital nerve,
supraorbital nerve and auriculotemporal nerve. Implanta-
tions were done uni or bilaterally.
Clinical outcomes, including Total Pain Index (TPI) (17),
patient satisfaction and complication rates, were docu-
mented before and after surgery. TPI (total pain index):
an integrated measure of the intensity and duration of
headache attacks over a two week period defined by the
Formula 1:
(1)
TPI = (D1x1) + (D2x2)
+ (D3x3)
where D1, number of hours with headache that is
slight, does not limit normal activity; D2, number of hours
with headache that is moderate, limiting normal activity
but does not confine patient to bed; D3, number of hours
of headache that is severe, limiting all activities causing pa-
tient to be bedridden (17).
All patients were seen approximately 14 days after the
procedure, then monthly for 6 months. Thereafter, they
were followed every six months, either at the clinic or by
a phone call, for 6 months to 9 years (average follow-up pe-
riod: 4.9 years). Outcome evaluation was done by asking
the patients about their pain intensity, as well as duration
and frequency of headaches, before the procedure and at
each follow-up interview. Patient’s satisfaction and treat-
ment complications (if any) were also documented. Statis-
tics:
We used student’s t-test to compare pain parameters
before treatment and at follow up. The level of statistical
significance was set at 0.01.
4. Results
We identified 24 patients (5 males, 19 females), who
had undergone PNS for their chronic refractory headaches.
Their mean age was 45.8 years (range: 22 - 66 yeas), and
their average headache duration was 10.3 years (range: 2 -
25 years). Patients were diagnosed with chronic migraine
(15/24), occipital neuralgia or cervicogenic headache
(9/24).
Three of the 24 patients were not followed after their
leads were removed. The remaining 21 patients were fol-
lowed periodically as described above.
All 24 patients experienced significant headache relief
for three months after permanent device implantation,
with a decrease in pain intensity, duration and frequency
(TPI). Mean TPI decreased significantly, from 516 ± 131 be-
fore the procedure to 74.8 ± 61.6 at the last follow up (P
< 0.00001). Three patients had their stimulator removed;
one due to skin erosion and infection at the silastic anchor
site (as mentioned above), the second due to skin allergic
reaction to the stimulation lead (18), and the third because
of her religious belief. The remaining twenty-one patients
have been followed since surgery. They have maintained
the same degree of pain relief throughout the follow up pe-
riod without significant complications.
Overall, the surgical outcomes were excellent in these
24 patients (Table 1). There were no acute post-operative
infections. In the early three patients of this group, silas-
tic anchors were used. One of them had lead migration
one year after implantation, requiring revision. The same
patient also developed scalp erosions on both sides at dif-
ferent times of treatment, requiring revision. After re-
implantation with modified technique without silastic an-
chors, he has had no further complications, keeping his
stimulation therapy. Another one of the early three pa-
tients developed skin erosion at the silastic anchor site two
years after implantation, requiring lead removal. Due to
these problems, the surgical technique was modified, with
significant reduction in complication rate (Tables 1 and 2).
After revision of the surgical technique, 21 consecutive pa-
tients were treated and evaluated. In this group, there were
no major post-operative complications, such as skin ero-
sions, infection or lead migrations. The self-rated treat-
ment satisfaction was excellent in 13 of the 24 (54%) pa-
tients, very good or good in 10 (42%), and fair in 1 (4%) pa-
tient.
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Table 1. Headache Characteristics Before and After Peripheral Scalp Neurostimulationa
No Sex Age, y History of HA HA Frequency HADuration TPI TPI Reduction
(%)
Nerve(s)
Stimulated
Self-Rated
Outcome
F/U Duration Comments
(See Tab 2)
Before After Before After Before After
1a F 47 14 daily rarely constant 2 h 574 140 75.6 L. occi
/supra/auri
good 9
2a M 48 5 daily 1 - 2/w constant 2 - 3 h 390 88 77.4 Bil.
occi/supra/auri
good 9 1
3a M 53 15 daily 1 - 2/w constant 2 - 3 h 854 124 85.5 Bil. occi excellent 2 2
4 F 54 15 daily none constant none 364 0 100 Bil. occi/supra excellent 5 3
5 F 46 6 daily rarely constant 2 - 3 h 630 28 95 Bil. occi /supra good 7 4
6 F 42 5 daily 2/w constant 2 - 3h 420 48 88.6 L. occi/supra good 7
7 F 62 15 daily 1 - 2/w constant 3 - 4 h 840 36 95.7 Bil. occi excellent 7
8 F 50 20 5/w none constant none 504 0 100 Bil. occi excellent 7
9 M 59 15 daily daily 8 - 9 hours 2 - 3 h 364 140 61.5 L. occi/supra fair 6
10 M 66 20 daily none 0.5 to 1 h none 336 0 100 L. occi/supra excellent 6
11 F 38 5 daily rarely constant 1 - 2 h 350 32 90.9 R. occi/supra excellent 6
12 F 50 20 daily rarely constant 1 - 2 h 364 32 91.2 R. occi/supra excellent 6
13 F 60 20 daily none constant none 434 0 100 L. occi excellent 6
14 F 41 3 daily 1/w constant 1-2 h 616 10 98.4 Bil.
cci/supra/auri
very good 6
15 F 51 5 daily 3/w constant 1 - 2 h 504 16 96.8 Bil. occi excellent 6
16 M 31 3 daily none 8 - 12 h none 390 0 100 L. occi/supra excellent 5
17 F 33 2 daily rarely constant 0.5 - 1 h 476 4 99.2 R. occi/supra excellent 4
18 F 23 3 daily 3 - 5/w constant 2 - 3 h 532 124 76.7 Bil. supra good 4
19 F 48 5 daily 2 - 3/w constant 2 - 3 h 530 120 77.3 R. occi/auri excellent 4
20 F 37 3.5 daily 3/w constant 1 - 2 h 420 96 77.1 R. occi/supra good 2.5
21 F 24 5 daily daily constant 12 h 840 336 60 Bil. occi/supra good 1.5
22 F 22 13 daily daily constant 14 h 868 280 68 Bil. occi/supra good 1.5
23 F 56 25 daily rarely constant 1 - 2 h 360 60 83.3 Bil. occi excellent 0.3 5
24 F 58 5 daily rarely constant 2 - 3 h 435 80 81.6 Bil. occi good 0.3 6
Abbreviations: Freq, frequency; HA, headache; Dur, duration; Bil, bilateral; L, left; R, right; h, hour; F/U, follow-up; occi, occipital nerve; supra, supraorbital nerve; auri, auriculotemporal nerve.
a Patients number 1 - 3 were the early cases with silastic anchors. The other patients (numbers 4 - 24) were treated using the revised surgical technique.
Table 2. The Complications and Comments from Table 1
No. Complications Years after the implant Management Outcome
1 Excellent. Pt remained with leads
One supraorbital lead migration 1 year Lead revision
Infection over one side of plastic anchor due
to skin erosion
1.5 years Local debridement & lead revision
Infection at the other side due to a similar
cause
2 years Lead revision
2 Infection over the plastic anchor due to skin
erosion
2 years Device removal
3 Pain at the battery sites (subclavicular) 3 years Batteries relocated from the infraclavicular
fossa to the buttocks
Excellent. Pt remained with leads
4 Infection at neck over the anchor knot 4 years Debridement Excellent. Pt remained with leads
5 Skin allergic reaction to the lead component 3 months Failed conservative therapy & device
removal (18).
6 The patient reported significant headache
reduction after implantation. However,
three months later she requested device
removal due to her religious beliefs.
3 months Device removal
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5. Discussion
We found that PNS of various nerves in the cranial area
was effective and well tolerated in our patients with previ-
ously refractory chronic headaches. The mechanism of the
analgesic effect of peripheral neurostimulation may be re-
lated to activation of large fiber sensory afferents, that in
turn inhibit nociceptive fiber activity (15).
In a previous study, Schwedt et al. (4) reported on a
mean subjective pain improvement of 52 after occipital
nerve stimulator implantation in 15 patients with refrac-
tory headaches of various etiologies, however, most pa-
tients required lead revision within 1 year. Our efficacy re-
sults are comparable to those reported in that study, with
a lower complication rate, possibly due to our technique
modifications.
5.1. Selecting Scalp Nerve(s) for PNS (Figure 1)
In order to achieve better headache relief, selecting cra-
nial nerves for PNS therapy is important, which is based on
the patient’s clinical presentation and headache location.
The historical database for PNS therapies suggests that con-
cordant neurostimulation may provide better headache
relief than a non-concordant one (15, 19). If the patient
presents with one-sided occipital headache, a single 8-
electrode lead with regular contact and contact spacing
lead is applied to cover all three occipital nerves (greater,
lesser, and third ) unilaterally. If the patient presents
with headache at the occipital and frontal regions, two 8-
electrode leads are used, one for the occipital nerves, and
the other for supraorbital and supratrochlear nerves, re-
spectively (Figure 1 top left). If the patient presents with
headache at the occipital, frontal and temporal regions,
an 8-electrode lead is used for the occipital nerves, one 4-
electrode with wide electrode contact spacing lead is used
to cover the supraorbital and supratrochlear nerves, and
one 4-electrode with small contact spacing lead to the au-
riculotemporal nerve (Figure 1 top right). Two 4-electrode
leads are converted to the 8-contact extension lead; the lat-
ter with the other 8-electrode lead is connected to the same
implantable pulse generator (IPG). If the patient presents
with bilateral occipital headache, two 8-electrode leads are
used for both sides of the occipital nerves (Figure 1 bot-
tom left). If the headache is at the occipital and frontal re-
gions bilaterally, based on the clinical presentation, multi-
ple leads are used (Figure 1 bottom right). We found that
leads from a unilateral side (occipital and supraorbital)
connected to the same IPG provide better pain relief com-
pared with two occipital leads connected to one IPG and
the other two supraorbital leads connected to a different
IPG. We believe that the frontal and occipital leads from
the same IPG can produce a broad paresthesia (cross talk
electro-magnetic field) between these two leads, which
gives better pain relief. The current 32-contact devices al-
low the use of 4 independent 8-contact electrodes with a
single IPG.
5.2. Surgical Technique of PNS
Common complications of PNS include infection, skin
erosion and lead migration (3, 4, 6-8, 14, 16). After encoun-
tering these complications in our early cases, we have mod-
ified our surgical techniques. In our twenty-one patients
treated with modified technique, none developed lead mi-
gration, skin erosion and scalp infection.
The followings are the key points of permanent im-
plantation of PNS. The skin need to be appropriately pre-
pared with haircut at least 3 inches from the incision sites,
and marked for the incision and needle entrance. When
selecting the incision and needle entrance sites, the cos-
metic and soft tissue factors (to cover the lead and anchors)
should be considered. After the incision is made, mini-
mally invasive hemostasis techniques are used to prevent
skin and subcutaneous tissue damaged, because the dam-
age can cause a difficulty to close the incision and result
in infection. After exploring the fascia and making a sub-
cutaneous space between scalp and fascia, two 2 - 0 non-
absorbable sutures are sutured and tightened to the galea
aponeurotica (fascia) as anchors with 0.5 to 0.8 inch apart
as a tension releasing loop (Figure 2). A pre-bent intro-
ducer is inserted through the incision toward the target
nerves. After the introducer reaches the appropriate posi-
tion, the PNS lead without a stylet is inserted under fluoro-
scopic guidance. After removal of the introducer, the PNS
lead is directly tightened to the galea aponeurotica as an
anchor. In order to prevent lead migration, it is very impor-
tant to tighten the suture with a standard technique. We
found that directly tightening the PNS lead will not cause
any damage to it (in our group for 9 years of follow-up). It
may require multiple tension releasing loops for the PNS
leads relaying to the IPG. When tunneling the introducer
from the temple to the occipital region, the needle should
be away from the superior part of the external ear in order
to prevent glasses earpieces irritating the lead or causing
skin breakdown. Each layer of scalp tissue should be closed
properly. If the tip of the PNS lead is found penetrating the
skin or tilted towards the skin, the PNS tip can be buried
deeply using a retrograde technique (20). After surgery,
the patient should avoid rapid or extreme flexion and ex-
tension of the spine for several weeks, to allow fibrosis and
firm attachment of the leads to the surrounding tissue.
5.3. Summary
Our results support the use of PNS in some patients
with refractory chronic headaches, and add to the exist-
4 Anesth Pain Med. 2016; 6(4):e35983.
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Figure 1. Stimulation Sites for Chronic Headache: Occipital, Supratrochlear and Supraorbital Cranial Nerve Stimulation (Top Left)
Occipital, supraorbital, supratrochlear and auriculotemporal nerve stimulation (top right). Bilateral occipital nerve stimulation, (bottom left). Bilateral occipital and supraor-
bital nerve stimulation (bottom right).
Anesth Pain Med. 2016; 6(4):e35983. 5
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Figure 2. Tension Release Loop
ing data on this treatment modality. Selecting the appro-
priate cranial nerve(s) for PNS therapy is essential to max-
imize the headache relief. An appropriate and meticulous
surgical technique is crucial to prevent procedure-related
complications; most commonly lead migration, skin ero-
sion and infections.
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